University of Minnesota

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Minnesota sits in the top decile of US sponsors by registered trial count (#33 of 15,742 sponsors by registered trial count).

966 total trials 180 currently recruiting 671 completed early-phase tilt top decile by trial count

University of Minnesota: 966 sponsored US clinical trials, 180 recruiting.

University of Minnesota sponsors 966 registered US clinical trials on ClinicalTrials.gov, 180 of them currently recruiting, and 671 completed. 71 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 14 trials.

Top-decile sponsor footprint

University of Minnesota ranks in the top decile of sponsors by registered trial count (#33 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

671 of 731 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

966 total, page 18 of 20

COMPLETED Phase 2

Memantine Treatment of Compulsive Buying

NCT00830375

COMPLETED NA

A Randomized Trial of Ostomy Closure Techniques

NCT01713452

COMPLETED

Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers

NCT00897234

TERMINATED Phase 1

Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

NCT00863395

COMPLETED Phase 1

Determination of Absorption and Elimination of Lamotrigine-XR

NCT00789113

COMPLETED Phase 2

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

NCT00749658

COMPLETED Phase 2

Innovative Interventions for Smoking Cessation

NCT01050569

COMPLETED

Problems With Immune Recovery in the Gut Tissue

NCT01460433

COMPLETED

Tissue Drug Levels of HIV Medications

NCT01490346

COMPLETED NA

Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers

NCT00711100

COMPLETED Phase 1

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

NCT00753493

COMPLETED NA

Gastrointestinal Toleration of Inulin Products

NCT00958529

COMPLETED NA

Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers

NCT00958399

COMPLETED Phase 1

Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia

NCT01884064

COMPLETED Phase 3

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

NCT00880919

TERMINATED Phase 3

Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

NCT00958139

COMPLETED Phase 4

Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings

NCT00685035

COMPLETED

A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty

NCT00684749

COMPLETED NA

A Study to Determine the Effectiveness of a Self-regulation Program to Treat Pediatric Obesity

NCT01442142

COMPLETED

Management of Bleeding Following Cardiopulmonary Bypass

NCT00672516

COMPLETED NA

Human Laboratory Study Of Varenicline in Smokers

NCT00709696

COMPLETED

Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae

NCT00850655

COMPLETED

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

NCT00613613

COMPLETED

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

NCT00793741

COMPLETED Phase 1

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

NCT00553969

COMPLETED NA

Intervention to Improve Expression of End of Life Preferences for Homeless Persons

NCT00546884

COMPLETED Phase 1

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

NCT00575185

COMPLETED NA

Satiety Response After Mixed Fiber Doses

NCT00889993

TERMINATED Phase 1

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204

COMPLETED Phase 1

Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine

NCT01092650

COMPLETED Phase 1

Repetitive Transcranial Magnetic Stimulation (rTMS) to Promote Hand Recovery in Stroke

NCT00913211

COMPLETED

Alport Syndrome Treatments and Outcomes Registry

NCT00481130

COMPLETED Phase 3

Improving Varenicline Adherence and Outcomes in Homeless Smokers

NCT00786149

COMPLETED Phase 2

Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study

NCT00515177

COMPLETED

A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome

NCT00622544

COMPLETED NA

Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults

NCT01497158

COMPLETED NA

Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes

NCT00700908

COMPLETED Phase 2

Double-Blind Naltrexone in Compulsive Sexual Behavior

NCT00467558

COMPLETED Phase 2

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT00484679

TERMINATED

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00536523

COMPLETED Phase 3

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

NCT00457977

TERMINATED Phase 3

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

NCT00493974

COMPLETED Early Phase 1

Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation

NCT00397436

COMPLETED Phase 2

Health Effects of SLT, Cigarette Smoking, and New Tobacco Products

NCT00469079

COMPLETED NA

Effect of Vitamin D Deficiency and Vitamin D Supplementation on Glucose Metabolism

NCT00749918

COMPLETED Phase 1

Ankle Tracking Training in Stroke

NCT01298583

COMPLETED Phase 4

The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment

NCT00407199

COMPLETED NA

Parents As The Agent Of Change For Childhood Obesity (PAAC)

NCT01066910

COMPLETED Phase 2

Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use

NCT00218296

COMPLETED Phase 1

Calcineurin Inhibitor Sparing After Kidney Transplantation

NCT01062555

← Previous Page 18 of 20 Next →

Phase Distribution

PhaseTrial count
Phase 1 123
Phase 2 83
Phase 3 35
Phase 4 36

What is open in the University of Minnesota pipeline

180 recruiting of 966 indexed (19% open); 671 completed (69%).

Phase mix: 71 late (III/IV) vs 206 early (I/II) (early-phase heavy).

Top condition: Obesity (14 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Minnesota: open-pipeline peers nationwide

Peers matched on 966 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Minnesota sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20% Total trials Recruiting share University of MinnesotaColumbia UniversityBrigham and Women's HospitalHoffmann-La RocheBristol-Myers SquibbUniversity of Alabama at BirminghamMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Minnesota sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Minnesota sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 966 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Minnesota page

966 registered trials is a research-attention snapshot, not an endorsement of University of Minnesota or any single study.

  • 180 of University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Minnesota pipeline card: 966 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.